No Data
No Data
No Data
No Data
No Data
Alkermes (NASDAQ:ALKS) Shareholders Have Endured a 20% Loss From Investing in the Stock a Year Ago
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That
Simply Wall St13:50 ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanksApr 19 06:30 ET
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Dow JonesApr 19 06:27 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Moomoo 24/7Apr 19 06:17 ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanksApr 18 01:10 ET
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Yahoo FinanceApr 17 10:01 ET
Lionnell : small sell orders through $16.40
Lionnell : won't stay green
Simon backy : https://www.etfdailynews.com/2022/04/28/vaxxinity-inc-nasdaqvaxx-insider-mei-mei-hu-buys-8038-shares/
No Data
No Data